Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2001

View Archived Issues

Licensing opportunity from NIH: novel retroviral vectors for DNA transfer and gene reconstitution

Licensing opportunity from NIH: NSAID-related gene with antitumorigenic properties

Progress reported by Chiron in product pipeline during 2000

Oxigene discusses development progress

Protegrin IB-367 phase I results in ventilator-associated pneumonia reported

MGI Pharma signs letter of intent for exclusive North American license to palonosetron

Two of British Biotech's MMPIs show no advantage over placebo

Roche and deCODE Genetics identify new targets for schizophrenia and PAOD

Combination of PS-519 + thrombolysis may be superior to either therapy alone in embolic stroke

InSite Vision provides product overview

Spin trap agents, with or without tPA, and thromboembolic stroke

Xenerex Biosciences acquires patent to human antibody generation process

Switch Biotech acquires delivery system for skin wounds

Clinically achievable doses of human albumin provide significant neuroprotection in ischemic stroke

ApoA-I Milano shows activity in mouse model of atherosclerotic disease

News from International Stroke Conference: substantial clinical efficacy predicted for NXY-059

Continued progress in product pipeline reported at Interneuron

Intramuscular formulation of Zyprexa clears hurdle on the way to FDA approval

Merck KGaA licenses antidepressant to GlaxoSmithKline

New benzimidazoles useful for atherosclerosis Rx designed at Japanese lab

Takeda claims potent new factor Xa inhibitors

Novel alpha1B-adrenoceptor antagonists from Toray particularly useful in hypertension

New agents for osteoporosis act by inhibiting osteoclast vacuolar ATPase

Antitumor agents derived from UCF-116 result from Kyowa Hakko-Lilly collaboration

Preparation, activity and use of specific IkappaB kinase inhibitors claimed by Aventis

Onconase receives orphan medicinal product designation in Europe

Series of international patents issued to Bayer for new agents for anemia

New oral formulation of Zomig approved by FDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...